Artiva Biotherapeutics
Develops allogeneic natural killer cell-based therapies for various diseases.
Company facts
- Founded
- 2019
- Employees
- 106
- Headquarters
- United States
- CEO
- Fred Aslan
- Type
- Public
- Listed
- NASDAQ: ARTV
About
Artiva Biotherapeutics is a clinical-stage biotechnology company dedicated to developing highly effective, off-the-shelf, allogeneic natural killer (NK) cell therapies for patients with devastating autoimmune diseases. Founded in 2019 as a spin-out of GC Cell Corporation (formerly GC Lab Cell Corporation), a leading healthcare company in the Republic of Korea, Artiva is headquartered in San Diego, California, where it has established a purpose-built 9,000 square foot cell production center compliant with current Good Manufacturing Practices (cGMP). The company's lead product candidate, AlloNK®, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) such as rituximab. The company's manufacturing-first approach enables production sufficient to treat over 1,000 autoimmunity patients annually, with the mission of making these transformative therapies broadly accessible in community settings. Artiva's approach leverages the compelling cell-killing properties of NK cells combined with mAbs for targeting, offering potential advantages in safety and accessibility compared to existing autologous cell therapies.